B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients

Critical Care

Volumn 17, Issue 6, 2013, Pages

  Shubin, Nicholas J ^a   Monaghan, Sean F ^a   Heffernan, Daithi S ^a   Chung, Chun Shiang ^a   Ayala, Alfred ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR RECEPTOR; CELL RECEPTOR; UNCLASSIFIED DRUG; BTLA PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR;

ABDOMINAL INFECTION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HOSPITAL INFECTION; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; INTENSIVE CARE; LENGTH OF STAY; LUNG INFECTION; LYMPHOCYTE; LYMPHOID ORGAN; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SKIN INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; URINARY TRACT INFECTION; ANIMAL; BLOOD; C57BL MOUSE; CROSS INFECTION; IMMUNOLOGY; INTENSIVE CARE UNIT; METABOLISM; PROGNOSIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MICE, INBRED C57BL; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; SEPSIS;

EID: 84888270655     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13131     Document Type: Article

References (44)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006, 6:207-212. 10.2174/187153006777442332, 16787296.
3. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2001, 2003:1250-1256.
4. Angus DC. The search for effective therapy for sepsis: back to the drawing board?. JAMA 2011, 306:2614-2615. 10.1001/jama.2011.1853, 22187284.
5. Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C, Crozon J, Faure A, Guillaume C, Marcotte G, Vulliez A, Monneuse O, Monneret G. Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care 2010, 14:R208. 10.1186/cc9331, 3220028, 21092108.
6. Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L, Cupa M, Cohen Y. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006, 34:102-107. 10.1097/01.CCM.0000195012.54682.F3, 16374163.
7. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402. 10.1164/ajrccm.164.3.2009052, 11500339.
8. Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure?. Curr Opin Infect Dis 2012, 25:328-336. 10.1097/QCO.0b013e3283522038, 22421751.
9. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150. 10.1056/NEJMra021333, 12519925.
10. Hotchkiss RS, Opal S. Immunotherapy for sepsis - a new approach against an ancient foe. N Engl J Med 2010, 363:87-89. 10.1056/NEJMcibr1004371, 20592301.
11. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999, 162:4148-4156.
12. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg REJ, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001, 166:6952-6963.
13. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD2, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605. 10.1001/jama.2011.1829, 3361243, 22187279.
14. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 1977, 186:241-250. 10.1097/00000658-197709000-00002, 1396336, 142452.
15. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J, Lepape A, Ayala A, Monneret G. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009, 35:678-686. 10.1007/s00134-008-1337-8, 2789433, 18946659.
16. Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008, 83:523-535.
17. Cavassani KA, Carson WFT, Moreira AP, Wen H, Schaller MA, Ishii M, Lindell DM, Dou Y, Lukacs NW, Keshamouni VG, Hogaboam CM, Kunkel SL. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010, 115:4403-4411. 10.1182/blood-2009-09-241083, 2881495, 20130237.
18. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003, 4:670-679.
19. Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells. J Immunol 2005, 174:3377-3385.
20. Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM. B and T lymphocyte attenuator regulates T cell survival in the lung. J Immunol 2008, 181:2973-2979. 2743426, 18713967.
21. Mellman I, Couko G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489. 10.1038/nature10673, 22193102.
22. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931. 10.1056/NEJMoa1112824, 3345206, 22397654.
23. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009, 229:114-125. 10.1111/j.1600-065X.2009.00767.x, 3424066, 19426218.
24. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240. 10.1189/jlb.0110037, 20483923.
25. Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS. Dose dependent effect of anti-CTLA-4 on survival in sepsis. Shock 2011, 36:38-44. 10.1097/SHK.0b013e3182168cce, 3412306, 21368717.
26. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15:R70. 10.1186/cc10059, 3222003, 21349174.
27. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15:R99. 10.1186/cc10112, 3219369, 21418617.
28. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92:593-603. 10.1189/jlb.1211641, 3427605, 22459947.
29. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA 2009, 106:6303-6308. 10.1073/pnas.0809422106, 2669369, 19332785.
30. Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. Biochem Biophys Res Commun 2006, 344:1121-1127. 10.1016/j.bbrc.2006.03.242, 16643847.
31. Bandyopadhyay G, De A, Laudanski K, Li F, Lentz C, Bankey P, Miller-Graziano C. Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med 2007, 35:794-801. 10.1097/01.CCM.0000256847.61085.A5, 17255857.
32. Zhang Z, Xu X, Lu J, Zhang S, Gu L, Fu J, Jin L, Li H, Zhao M, Zhang J, Wu H, Su L, Fu YX, Wang FS. B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. J Infect Dis 2011, 203:1668-1678. 10.1093/infdis/jir165, 21592997.
33. Shubin NJ, Chung CS, Ayala A. B and T lymphocyte attenuator (BTLA) is a contributor to the pathological progression of sepsis [abstract]. Inflamm Res 2010, 59:S22.
34. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). Circ Shock 1992, 36:191-199.
35. Liu X, Alexiou M, Martin-Orozco N, Chung Y, Nurieva RI, Ma L, Tian Q, Kollias G, Lu S, Graf D, Dong C. Cutting edge: a critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 2009, 182:4516-4520. 10.4049/jimmunol.0803161, 2767106, 19342624.
36. Adler G, Steeg C, Pfeffer K, Murphy TL, Murphy KM, Langhorne J, Jacobs T. B and T lymphocyte attenuator restricts the protective immune response against experimental malaria. J Immunol 2011, 187:5310-5319. 10.4049/jimmunol.1101456, 21998455.
37. Serriari NE, Gondois-Rey F, Guillaume Y, Remmerswaal EB, Pastor S, Messal N, Truneh A, Hirsch I, van Lier RA, Olive D. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J Immunol 2010, 185:3140-3148. 10.4049/jimmunol.0902487, 20693422.
38. Sun Y, Brown NK, Ruddy MJ, Miller ML, Lee Y, Wang Y, Murphy KM, Pfeffer K, Chen L, Kaye J, Fu YX. B and T lymphocyte attenuator tempers early infection immunity. J Immunol 2009, 183:1946-1951. 10.4049/jimmunol.0801866, 2895307, 19587015.
39. Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010, 120:157-167. 10.1172/JCI40070, 2799219, 20038811.
40. Paulos CM, June CH. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest 2010, 120:76-80. 10.1172/JCI41811, 2798708, 20038807.
41. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002, 17:463-467. 10.1097/00024382-200206000-00004, 12069181.
42. Jeong SJ, Song YG, Kim CO, Kim HW, Ku NS, Han SH, Choi JY, Kim JM. Measurement of plasma sTREM-1 in patients with severe sepsis receiving early goal-directed therapy and evaluation of its usefulness. Shock 2012, 37:574-578. 10.1097/SHK.0b013e318250da40, 22395243.
43. Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, De Carvalho Bittencourt M, Quenot JP, Bollaert PE, Faure G, Charles PE. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012, 186:65-71. 10.1164/rccm.201201-0037OC, 22538802.
44. Wang XF, Chen YJ, Wang Q, Ge Y, Dai Q, Yang KF, Fang X, Zhou YH, Hu YM, Mao YX, Zhang XG. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. Tissue Antigens 2007, 69:145-153. 10.1111/j.1399-0039.2006.00710.x, 17257317.